Eligibility in Bleeding and Thrombosis During ECMO

Eligibility
Study Description
Bleeding and thrombosis represent major adverse events during extracorporeal membrane oxygenation (ECMO). Complications resulting from these events can lead to death or need for long term rehabilitation support. Despite the increasing use of extracorporeal support and new technology which makes it simpler and potentially safer to apply, little scientific information regarding the predictors of bleeding or thrombosis exists.

This project sought to describe the incidence of bleeding and thrombosis in ECMO patients at Collaborative Pediatric Critical Care Research Network (CPCCRN) sites and to describe current anticoagulation monitoring practices. Additionally, it sought evidence of association between bleeding and thrombotic complications, laboratory coagulation measurements, patient characteristics, ECMO circuitry, and adherence to center-specific ECMO management protocols. Data was collected on 514 subjects receiving ECMO at CPCCRN sites over a 21-month period. Data was collected on 514 subjects receiving ECMO at CPCCRN sites over a 21-month period.

入选标准
研究概况
出血与血栓形成是体外膜肺氧合（ECMO）治疗期间的主要不良事件。此类事件引发的并发症可导致患者死亡，或需长期康复支持。尽管体外支持技术的应用日益广泛，且新技术使其操作更简便、应用更具安全性，但目前关于出血或血栓形成预测因素的科学研究资料仍较为匮乏。
本研究旨在描述合作儿科重症护理研究网络（CPCCRN）各中心收治的ECMO患者中出血与血栓形成的发生率，并梳理当前的抗凝监测实践现状。此外，本研究还旨在探讨出血与血栓并发症、实验室凝血检测指标、患者基线特征、ECMO管路系统以及各中心ECMO管理方案依从性之间的关联证据。研究在21个月的周期内，收集了CPCCRN各中心收治的514名接受ECMO治疗患者的相关数据。研究在21个月的周期内，收集了CPCCRN各中心收治的514名接受ECMO治疗患者的相关数据。